BioAge is a clinical-stage biotechnology company building BGE-102, an oral, brain-penetrant NLRP3 inhibitor, across cardiometabolic and retinal diseases; its nearer-term story is execution on two Phase 2 programs, QUELL-CV and QUELL-DME.
The DME trial has begun, but the milestone was already public. The filing confirms that the first participant was dosed in QUELL-DME, a roughly 180-person randomized Phase 2 study of BGE-102 in diabetic macular edema. 〔0〕 That same start was publicly announced on September 8, 2026, so the October 2 filing is confirmation rather than a fresh clinical surprise.
The design gives BioAge two shots at proving the drug’s role, not efficacy yet. Participants are split among anti-VEGF plus placebo, anti-VEGF plus BGE-102, and BGE-102 alone with a sham injection. 〔1〕 That structure tests both whether BGE-102 can work as an oral standalone treatment and whether it can improve standard anti-VEGF therapy, but the filing contains no patient outcomes or safety readout.
The timeline is unchanged and remains distant. The primary endpoint is change in best-corrected visual acuity at week 12, with topline results expected in the second half of 2027. 〔2〕 That leaves QUELL-CV’s expected second-half 2026 data as the next meaningful clinical test of BGE-102, not this filing.
Bottom line: The business is progressing on schedule, but this October 2 filing does not materially change BioAge’s story because the DME start, design, and 2027 readout timing were already disclosed on September 8, 2026.
Read the original 8-K on SEC EDGAR ↗